Page 214 - 2020_07-Haematologica-web

F. Paciullo et al.
Pathol. 1992;97(5):652-655.
21. Gruel Y, Pacouret G, Bellucci S, Caen J. Severe proximal deep vein thrombosis in a Glanzmann thrombasthenia variant suc- cessfully treated with a low molecular weight heparin. Blood. 1997;90(2):888-890.
22. Shpilberg O, Rabi I, Schiller K, et al. Patients with Glanzmann thrombasthenia lacking platelet glycoprotein alpha(IIb)beta(3) (GPIIb/IIIa) and alpha(v)beta(3) receptors are not protected from atherosclerosis. Circulation. 2002;105 (9):1044-1048.
23. Seretny M, Senadheera N, Miller E, Keeling D. Pulmonary embolus in Glanzmann's thrombasthenia treated with warfarin. Haemophilia. 2008;14(5):1138-1139.
24. Girolami A, Vettore S, Vianello F, Berti de Marinis G, Fabris F. Myocardial infarction in two cousins heterozygous for ASN41HIS autosomal dominant variant of Bernard-Soulier syndrome. J Thromb Thrombolysis. 2012;34(4):513-517.
25. Noris P, Schlegel N, Klersy C, et al. Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocy- topenia. Haematologica. 2014;99(8):1387- 1394.
26. Civaschi E, Klersy C, Melazzini F, et al. Analysis of 65 pregnancies in 34 women with five different forms of inherited platelet function disorders. Br J Haematol. 2015;170(4):559-563.
27. Gresele P, Subcommittee on Platelet Physiology of the International Society on T, Hemostasis. Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH. J Thromb Haemost. 2015;13(2):314-322.
28. Poon MC, d'Oiron R, Zotz RB, et al. The international, prospective Glanzmann Thrombasthenia Registry: treatment and
outcomes in surgical intervention.
Haematologica. 2015;100(8):1038-1044.
29. Crous-Bou M, Harrington LB, Kabrhel C. Environmental and genetic risk factors asso- ciated with venous thromboembolism. Semin Thromb Hemost. 2016;42(8):808-
820.
30. National Institute for Health and Care
Excellence. Venous thromboembolism in over 16s: reducing the risk of hospital- acquired deep vein thrombosis or pul- monary embolism. London, 2018. Available from: nice.org.uk/guidance/ng89.
31. Wall C, Moore J, Thachil J. Catheter-related thrombosis: A practical approach. J Intensive Care Soc. 2016;17(2):160-167.
32. Bates SM, Jaeschke R, Stevens SM, et al. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl 2): e351S-e418S.
thromboprophylaxis across the continuum of care for surgical patients. Adv Ther. 2010;27(2):81-93.
38. Dentali F, Malato A, Ageno W, et al. Incidence of venous thromboembolism in patients undergoing thoracotomy for lung cancer. J Thorac Cardiovasc Surg. 2008; 135(3):705-706.
39. Sachdeva A, Dalton M, Lees T. Graduated compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev. 2018;11:CD001484.
40. Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon. 2005;51(2-3):70-78.
41. Bikdeli B, Jimenez D, Hawkins M, et al. Rationale, design and methodology of the computerized registry of patients with venous thromboembolism (RIETE). Thromb Haemost. 2018;118(1):214-224.
42. Marassi A, Balzano G, Mari G, et al. Prevention of postoperative deep vein thrombosis in cancer patients. A random- ized trial with low molecular weight heparin (CY 216). Int Surg. 1993;78(2):166-
33. Caprini JA, Arcelus JI, Hasty JH, Tamhane
AC, Fabrega F. Clinical assessment of
venous thromboembolic risk in surgical 170.
patients. Semin Thromb Hemost. 1991;17
Suppl 3:304-312.
34. Miller AB, Hoogstraten B, Staquet M,
Winkler A. Reporting results of cancer
treatment. Cancer. 1981;47(1):207-214.
35. Daley MJ, Ali S, Brown CV. Late venous thromboembolism prophylaxis after cran- iotomy in acute traumatic brain injury. Am
Surg. 2015;81(2):207-211.
36. Ho KM, Bham E, Pavey W. Incidence of
venous thromboembolism and benefits and risks of thromboprophylaxis after cardiac surgery: a systematic review and meta- analysis. J Am Heart Assoc. 2015; 4(10):e002652.
37. Amin AN, Lin J, Ryan A. Need to improve
43. Bergqvist D, Benoni G, Bjorgell O, et al. Low-molecular-weight heparin (enoxa- parin) as prophylaxis against venous thromboembolism after total hip replace- ment. N Engl J Med. 1996;335(10):696-700.
44. Kock HJ, Schmit-Neuerburg KP, Hanke J, Rudofsky G, Hirche H. Thromboprophylaxis with low-molecular- weight heparin in outpatients with plaster- cast immobilisation of the leg. Lancet. 1995;346(8973):459-461.
45. Lassen MR, Borris LC, Nakov RL. Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization. N Engl J Med. 2002;347(10):726-730.
1956
haematologica | 2020; 105(7)